Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …”

Mitigation (decreasing) scenario. by Fabio Correddu (12501799)

Mean slope of the targeted variable cadence and the two potentially co-varying variables duty factor and speed as a function of acoustically paced cadence modulations (center rows)... by Anouk Nijs (17598622)

Bacterial load in lung and spleen of binge-drinking mice intranasally infected with decreasing doses of <i>B</i>. <i>thailandensis</i>. by Victor M. Jimenez Jr. (8107853)

Fluorescent micrographs showing a decrease in EGFP emissions by RNAi-based gene silencing in <i>ex vivo</i> cultured cells. by Kazuyo Watanabe (11473473)

“…<i>Ex vivo</i> cells were transfected with the IE2::EGFP vector (<b>A</b> and <b>E</b>, IE2::EGFP), transfected with the IE2::EGFP vector and the application of <i>egfp</i> dsRNA (<b>B</b> and <b>F</b>, +<i>egfp</i> dsRNA), and transfected with the IE2::EGFP vector and application of <i>kmo</i> dsRNA (<b>C</b> and <b>G</b>, +<i>kmo</i> dsRNA). …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

“…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”